226 related articles for article (PubMed ID: 21536145)
1. Histology and time to progression predict survival for lymphoma recurring after reduced-intensity conditioning and allogeneic hematopoietic cell transplantation.
Ram R; Gooley TA; Maloney DG; Press OW; Pagel JM; Petersdorf SH; Shustov AR; Flowers ME; O'Donnell P; Sandmaier BM; Storb RF; Gopal AK
Biol Blood Marrow Transplant; 2011 Oct; 17(10):1537-45. PubMed ID: 21536145
[TBL] [Abstract][Full Text] [Related]
2. Relapse of lymphoma after allogeneic hematopoietic cell transplantation: management strategies and outcome.
Wudhikarn K; Brunstein CG; Bachanova V; Burns LJ; Cao Q; Weisdorf DJ
Biol Blood Marrow Transplant; 2011 Oct; 17(10):1497-504. PubMed ID: 21338707
[TBL] [Abstract][Full Text] [Related]
3. Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomas.
Warlick ED; Tomblyn M; Cao Q; Defor T; Blazar BR; Macmillan M; Verneris M; Wagner J; Dusenbery K; Aurora M; Bachanova V; Brunstein C; Burns L; Cooley S; Kaufman D; Majhail NS; McClune B; McGlave P; Miller J; Oran B; Slungaard A; Vercellotti G; Weisdorf DJ
Biol Blood Marrow Transplant; 2011 Jul; 17(7):1025-32. PubMed ID: 21047561
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome.
Armand P; Kim HT; Ho VT; Cutler CS; Koreth J; Antin JH; LaCasce AS; Jacobsen ED; Fisher DC; Brown JR; Canellos GP; Freedman AS; Soiffer RJ; Alyea EP
Biol Blood Marrow Transplant; 2008 Apr; 14(4):418-25. PubMed ID: 18342784
[TBL] [Abstract][Full Text] [Related]
5. Higher Total Body Irradiation Dose Intensity in Fludarabine/TBI-Based Reduced-Intensity Conditioning Regimen Is Associated with Inferior Survival in Non-Hodgkin Lymphoma Patients Undergoing Allogeneic Transplantation.
Hamadani M; Khanal M; Ahn KW; Litovich C; Chow VA; Eghtedar A; Karmali R; Winter A; Fenske TS; Sauter C; Kharfan-Dabaja MA; Awan FT
Biol Blood Marrow Transplant; 2020 Jun; 26(6):1099-1105. PubMed ID: 32165327
[TBL] [Abstract][Full Text] [Related]
6. Survival of Lymphoma Patients Experiencing Relapse or Progression after an Allogeneic Hematopoietic Cell Transplantation.
Epperla N; Hamadani M; Ahn KW; He F; Kodali D; Kleman A; Hari PN; Pasquini M; Fenske TS; Craig MD; Kanate AS; Bachanova V
Biol Blood Marrow Transplant; 2018 May; 24(5):983-988. PubMed ID: 29410340
[TBL] [Abstract][Full Text] [Related]
7. Association of Reduced-Intensity Conditioning Regimens With Overall Survival Among Patients With Non-Hodgkin Lymphoma Undergoing Allogeneic Transplant.
Ghosh N; Ahmed S; Ahn KW; Khanal M; Litovich C; Aljurf M; Bacher VU; Bredeson C; Epperla N; Farhadfar N; Freytes CO; Ganguly S; Haverkos B; Inwards D; Kamble RT; Lazarus HM; Lekakis L; Murthy HS; Nishihori T; Ramakrishnan P; Rizzieri DA; Yared JA; Kharfan-Dabaja MA; Sureda A; Hamadani M
JAMA Oncol; 2020 Jul; 6(7):1011-1018. PubMed ID: 32496525
[TBL] [Abstract][Full Text] [Related]
8. Allotransplantation for patients age ≥40 years with non-Hodgkin lymphoma: encouraging progression-free survival.
McClune BL; Ahn KW; Wang HL; Antin JH; Artz AS; Cahn JY; Deol A; Freytes CO; Hamadani M; Holmberg LA; Jagasia MH; Jakubowski AA; Kharfan-Dabaja MA; Lazarus HM; Miller AM; Olsson R; Pedersen TL; Pidala J; Pulsipher MA; Rowe JM; Saber W; van Besien KW; Waller EK; Aljurf MD; Akpek G; Bacher U; Chao NJ; Chen YB; Cooper BW; Dehn J; de Lima MJ; Hsu JW; Lewis ID; Marks DI; McGuirk J; Cairo MS; Schouten HC; Szer J; Ramanathan M; Savani BN; Seftel M; Socie G; Vij R; Warlick ED; Weisdorf DJ
Biol Blood Marrow Transplant; 2014 Jul; 20(7):960-8. PubMed ID: 24641829
[TBL] [Abstract][Full Text] [Related]
9. Clinical Outcomes of Fludarabine and Melphalan With an 800 cGy Total Body Irradiation Conditioning Regimen in Patients With Refractory or Relapsed Aggressive Non-Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
Jeon YW; Yoon S; Min GJ; Park SS; Park S; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Lee JW; Cho SG
Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):345-355.e7. PubMed ID: 31014757
[TBL] [Abstract][Full Text] [Related]
10. Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma.
Epperla N; Ahn KW; Ahmed S; Jagasia M; DiGilio A; Devine SM; Jaglowski S; Kennedy V; Rezvani AR; Smith SM; Sureda A; Fenske TS; Kharfan-Dabaja MA; Armand P; Hamadani M
J Hematol Oncol; 2017 Jun; 10(1):117. PubMed ID: 28606176
[TBL] [Abstract][Full Text] [Related]
11. Impact of Pretransplantation (18)F-fluorodeoxy Glucose-Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma.
Bachanova V; Burns LJ; Ahn KW; Laport GG; Akpek G; Kharfan-Dabaja MA; Nishihori T; Agura E; Armand P; Jaglowski SM; Cairo MS; Cashen AF; Cohen JB; D'Souza A; Freytes CO; Gale RP; Ganguly S; Ghosh N; Holmberg LA; Inwards DJ; Kanate AS; Lazarus HM; Malone AK; Munker R; Mussetti A; Norkin M; Prestidge TD; Rowe JM; Satwani P; Siddiqi T; Stiff PJ; William BM; Wirk B; Maloney DG; Smith SM; Sureda AM; Carreras J; Hamadani M;
Biol Blood Marrow Transplant; 2015 Sep; 21(9):1605-11. PubMed ID: 25983043
[TBL] [Abstract][Full Text] [Related]
12. Assessment of the hematopoietic cell transplantation comorbidity index in non-Hodgkin lymphoma patients receiving reduced-intensity allogeneic hematopoietic stem cell transplantation.
Pollack SM; Steinberg SM; Odom J; Dean RM; Fowler DH; Bishop MR
Biol Blood Marrow Transplant; 2009 Feb; 15(2):223-30. PubMed ID: 19167682
[TBL] [Abstract][Full Text] [Related]
13. Impact of conditioning regimen intensity on the outcomes of peripheral T-cell lymphoma, anaplastic large cell lymphoma and angioimmunoblastic T-cell lymphoma patients undergoing allogeneic transplant.
Savani M; Ahn KW; Chen Y; Ahmed S; Cashen AF; Shadman M; Modi D; Khimani F; Cutler CS; Zain J; Brammer JE; Rezvani AR; Fenske TS; Sauter CS; Kharfan-Dabaja MA; Herrera AF; Hamadani M
Br J Haematol; 2022 Apr; 197(2):212-222. PubMed ID: 35106754
[TBL] [Abstract][Full Text] [Related]
14. Alternate donor hematopoietic cell transplantation (HCT) in non-Hodgkin lymphoma using lower intensity conditioning: a report from the CIBMTR.
Hale GA; Shrestha S; Le-Rademacher J; Burns LJ; Gibson J; Inwards DJ; Freytes CO; Bolwell BJ; Hsu JW; Slavin S; Isola L; Rizzieri DA; Gale RP; Laport GG; Montoto S; Lazarus HM; Hari PN
Biol Blood Marrow Transplant; 2012 Jul; 18(7):1036-1043.e1. PubMed ID: 22155506
[TBL] [Abstract][Full Text] [Related]
15. Impact of type of reduced-intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphoma.
Ahmed S; Ghosh N; Ahn KW; Khanal M; Litovich C; Mussetti A; Chhabra S; Cairo M; Mei M; William B; Nathan S; Bejanyan N; Olsson RF; Dahi PB; van der Poel M; Steinberg A; Kanakry J; Cerny J; Farooq U; Seo S; Kharfan-Dabaja MA; Sureda A; Fenske TS; Hamadani M
Br J Haematol; 2020 Aug; 190(4):573-582. PubMed ID: 32314807
[TBL] [Abstract][Full Text] [Related]
16. High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma.
Law LY; Horning SJ; Wong RM; Johnston LJ; Laport GG; Lowsky R; Shizuru JA; Blume KG; Negrin RS; Stockerl-Goldstein KE
Biol Blood Marrow Transplant; 2006 Jul; 12(7):703-11. PubMed ID: 16785059
[TBL] [Abstract][Full Text] [Related]
17. Myeloablative intravenous pharmacokinetically targeted busulfan plus fludarabine as conditioning for allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma.
Ayala E; Figueroa J; Perkins J; Kim J; Yue B; Riches M; Nishihori T; Locke F; Anasetti C; Kharfan-Dabaja MA
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):335-40. PubMed ID: 25659459
[TBL] [Abstract][Full Text] [Related]
18. Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma.
Devetten MP; Hari PN; Carreras J; Logan BR; van Besien K; Bredeson CN; Freytes CO; Gale RP; Gibson J; Giralt SA; Goldstein SC; Gupta V; Marks DI; Maziarz RT; Vose JM; Lazarus HM; Anderlini P
Biol Blood Marrow Transplant; 2009 Jan; 15(1):109-17. PubMed ID: 19135949
[TBL] [Abstract][Full Text] [Related]
19. Long-term survival and late relapse in 2-year survivors of autologous haematopoietic cell transplantation for Hodgkin and non-Hodgkin lymphoma.
Majhail NS; Bajorunaite R; Lazarus HM; Wang Z; Klein JP; Zhang MJ; Rizzo JD
Br J Haematol; 2009 Oct; 147(1):129-39. PubMed ID: 19573079
[TBL] [Abstract][Full Text] [Related]
20. Risk factors predicting graft-versus-host disease and relapse-free survival after allogeneic hematopoietic stem cell transplantation in relapsed or refractory non-Hodgkin's lymphoma.
Jeon YW; Yoon S; Min GJ; Park SS; Park S; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Lee JW; Cho SG
Ann Hematol; 2019 Jul; 98(7):1743-1753. PubMed ID: 31089793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
